SEP-631 Demonstrated Robust, Dose-Dependent Inhibition of Icatibant-Induced Skin Wheal Formation, with Complete Inhibition Observed at Doses as ...

Blueprint Medicines’ focus on Ayvakit continues to pay off, which has ample untapped revenue potential in advanced and indolent systemic mastocytosis. Additionally, their pipeline includes other ...

Barzolvolimab improved symptoms in chronic spontaneous urticaria, supporting mast cell targeting as a novel treatment strategy. Read more.

Eosinophils and mast cells are two types of immune cells with critical roles in responding to foreign assaults. When these cells do not function properly, several disease outcomes can develop (e.g.

Certain immune cells backstab their cellular coworkers during allergic reactions. Mast cells, the security patrols of the immune system, can trigger allergic inflammation when they run into unfamiliar ...